scholarly journals pH-responsive Functionalized Extracellular Vesicles as Targeted Doxorubicin Delivery Vehicles for the Treatment of Hepatocarcinoma

2021 ◽  
Vol 233 (5) ◽  
pp. S151-S152
Author(s):  
Yuyu Luo ◽  
Yijun Wang ◽  
Yingtang Gao ◽  
Ying Luo ◽  
Liaonan Zou
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jun-Kyu Kim ◽  
Young-Jin Youn ◽  
Yu-Bin Lee ◽  
Sun-Hwa Kim ◽  
Dong-Keun Song ◽  
...  

AbstractExtracellular vesicles (EVs) are membrane-derived heterogeneous vesicles that mediate intercellular communications. They have recently been considered as ideal vehicles for drug-delivery systems, and immune cells are suggested as a potential source for drug-loaded EVs. In this study, we investigated the possibility of neutrophils as a source for drug-loaded EVs. Neutrophil-like differentiated human promyelocytic leukemia cells (dHL-60) produced massive amounts of EVs within 1 h. The dHL-60 cells are also easily loaded with various cargoes such as antibiotics (penicillin), anticancer drug (paclitaxel), chemoattractant (MCP-1), miRNA, and Cas9. The EVs derived from the dHL-60 cells showed efficient incorporation of these cargoes and significant effector functions, such as bactericidal activity, monocyte chemotaxis, and macrophage polarization. Our results suggest that neutrophils or neutrophil-like promyelocytic cells could be an attractive source for drug-delivery EVs.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 492
Author(s):  
Charlotte A. René ◽  
Robin J. Parks

The central nervous system (CNS) is surrounded by the blood–brain barrier (BBB), a semipermeable border of endothelial cells that prevents pathogens, solutes and most molecules from non-selectively crossing into the CNS. Thus, the BBB acts to protect the CNS from potentially deleterious insults. Unfortunately, the BBB also frequently presents a significant barrier to therapies, impeding passage of drugs and biologicals to target cells within the CNS. This review provides an overview of different approaches to deliver therapeutics across the BBB, with an emphasis in extracellular vesicles as delivery vehicles to the CNS.


2021 ◽  
Vol 10 (5) ◽  
Author(s):  
Xingang Yao ◽  
Pin Lyu ◽  
Kyung Yoo ◽  
Manish Kumar Yadav ◽  
Ravi Singh ◽  
...  

2017 ◽  
Vol 27 (3) ◽  
pp. 172-188 ◽  
Author(s):  
Sybren L.N. Maas ◽  
Xandra O. Breakefield ◽  
Alissa M. Weaver

2020 ◽  
Vol 327 ◽  
pp. 296-315 ◽  
Author(s):  
Laura Cabeza ◽  
Gloria Perazzoli ◽  
Mercedes Peña ◽  
Ana Cepero ◽  
Cristina Luque ◽  
...  

2020 ◽  
Vol 10 (2) ◽  
Author(s):  
Gensheng Zhang ◽  
Xiaofang Huang ◽  
Huiqing Xiu ◽  
Yan Sun ◽  
Jiming Chen ◽  
...  

Cells ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 224 ◽  
Author(s):  
Katie E. Gilligan ◽  
Róisín M. Dwyer

In recent times, extracellular vesicles (EVs) have come under the spotlight as potential therapeutics for cancer, due to the relative ease of manipulation of contents and potential for tumor targeting. The use of EVs as delivery vehicles may bypass some of the negative effects associated with cell-based carriers, and there has been a major focus on defining EV subtypes, establishing transparent nomenclature, and isolation and characterization techniques. EVs are believed to be a fingerprint of the secreting cell and so researchers harness the positive aspects of a particular cell of origin, and can then further modify EV contents to improve therapeutic efficacy. In this review, we highlight studies employing EVs as cancer therapeutics that have reported on immune response. As we rapidly advance towards potential application in the clinical setting, the question of immune response to EV administration in the cancer setting has become critically important.


2019 ◽  
Vol 11 (492) ◽  
pp. eaav8521 ◽  
Author(s):  
Oscar P. B. Wiklander ◽  
Meadhbh Á. Brennan ◽  
Jan Lötvall ◽  
Xandra O. Breakefield ◽  
Samir EL Andaloussi

Extracellular vesicles (EVs) are nanometer-sized, lipid membrane–enclosed vesicles secreted by most, if not all, cells and contain lipids, proteins, and various nucleic acid species of the source cell. EVs act as important mediators of intercellular communication that influence both physiological and pathological conditions. Given their ability to transfer bioactive components and surmount biological barriers, EVs are increasingly being explored as potential therapeutic agents. EVs can potentiate tissue regeneration, participate in immune modulation, and function as potential alternatives to stem cell therapy, and bioengineered EVs can act as delivery vehicles for therapeutic agents. Here, we cover recent approaches and advances of EV-based therapies.


Sign in / Sign up

Export Citation Format

Share Document